Data from the in-trial period (full analysis set). Data are presented as HR (blue symbol) and corresponding 95% CI (error bars). Time from randomization to relevant endpoint was analyzed using a stratified Cox proportional hazards model with treatment as a categorical fixed factor and two-sided P values. Participants without events of interest were censored at the end of their in-trial period. For the subgroup analyses, estimated HR and corresponding CI were calculated in a Cox proportional hazards model with interaction between treatment groups and subgroup as a fixed factor. P interaction values for the test of no interaction effect between SGLT2i use and treatment using a score test are shown. There was no renal death in the SGLT2i use subgroup, which is not displayed here. MI, myocardial infarction.
